Corporate
News Releases
2025
March
Pharmaceuticals
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 62.5 KB)
Nutraceuticals
New Release: SOYJOY Black Sesame A Bold Sesame Experience with a Delightful Popping Texture and Roasted Aroma
Pharmaceuticals
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Is Now on Sale - Insurance coverage begins on March 1, 2025
February
Nutraceuticals
Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT
Corporate
Otsuka Holdings Receives Award by the Commissioner of the Consumer Affairs Agency at FY2024 Award for Good Practices of Consumer
Nutraceuticals
Otsuka Pharmaceutical to Offer "Wellness Energy" at the Expo 2025 Osaka, Kansai, JapanIntroducing a New Vision for "Shaping the Health of the Future"
Corporate
Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET BottlesPartnering with Its Factory to Promote a "Local Production and Local Recycling" Initiative for PET Bottles
Corporate
Otsuka Group Selected for CDP Climate Change A List for a Third Consecutive Year
January
Nutraceuticals
Otsuka Pharmaceutical Launches the "Conditioning Supporter Training Program"Encouraging the Practice of Self-Conditioning
Nutraceuticals
Otsuka Pharmaceutical Releases the Total Conditioning Handbook for Well-Being to Support Life Performance
Pharmaceuticals
MIREVO®, the first neuropsychological testing program in Japan to support dementia treatment, now available
Pharmaceuticals
Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
Pharmaceuticals